Kairos Pharma, Ltd.
KAPA
$0.34
-$0.02-5.28%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.52% | 78.64% | 121.36% | 108.78% | 57.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.77% | 138.32% | 182.84% | 141.43% | 76.91% |
| Operating Income | -80.77% | -138.32% | -182.84% | -141.43% | -76.91% |
| Income Before Tax | -64.85% | -109.26% | -84.68% | -134.85% | -78.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.85% | -109.26% | -84.68% | -134.85% | -78.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.85% | -109.26% | -84.68% | -134.85% | -78.08% |
| EBIT | -80.77% | -138.32% | -182.84% | -141.43% | -76.91% |
| EBITDA | -84.86% | -148.48% | -198.90% | -154.55% | -84.08% |
| EPS Basic | -8.54% | -32.62% | -18.57% | -73.46% | -43.68% |
| Normalized Basic EPS | 6.80% | -10.49% | -35.95% | -96.82% | -67.14% |
| EPS Diluted | -8.54% | -32.62% | -18.57% | -73.46% | -43.68% |
| Normalized Diluted EPS | 6.80% | -10.49% | -35.95% | -96.82% | -67.14% |
| Average Basic Shares Outstanding | 56.26% | 63.23% | 56.67% | 36.68% | 21.50% |
| Average Diluted Shares Outstanding | 56.26% | 63.23% | 56.67% | 36.68% | 21.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |